When the coronavirus hit, the Serum Institute of India, the world’s largest vaccine maker, seemed uniquely positioned to help. It struck a deal with AstraZeneca, promising a billion vaccine doses to low- and middle-income nations.
Earlier this year, a ban instituted by Prime Minister Narendra Modi put a stop to those plans.
What has that meant for the nations promised millions of doses?
Guest: Emily Schmall, a South Asia correspondent for The New York Times based in New Delhi.
Sign up here to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter.
Background reading:
- The Serum Institute vowed to protect its country from the coronavirus and inoculate the world’s poor, but India’s crisis has pushed it past its limits.
- Big-power muscle flexing helps explain many of the world’s vaccine inequities, but there’s another problem: The manufacturing challenge is unprecedented.
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
from The Daily https://ift.tt/2tIfdyq
When the coronavirus hit, the Serum Institute of India, the world’s largest vaccine maker, seemed uniquely positioned to help. It struck a deal with AstraZeneca, promising a billion vaccine doses to low- and middle-income nations.
Earlier this year, a ban instituted by Prime Minister Narendra Modi put a stop to those plans.
What has that meant for the nations promised millions of doses?
Guest: Emily Schmall, a South Asia correspondent for The New York Times based in New Delhi.
Sign up here to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter.
Background reading:
- The Serum Institute vowed to protect its country from the coronavirus and inoculate the world’s poor, but India’s crisis has pushed it past its limits.
- Big-power muscle flexing helps explain many of the world’s vaccine inequities, but there’s another problem: The manufacturing challenge is unprecedented.
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
https://ift.tt/eA8V8J
0 Comments :
Post a Comment
Please do not post the SPAM comment.